Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-01-01 Epub Date: 2024-11-29 DOI:10.1080/14796694.2024.2426443

Faiz Anwer, Tommy Lan, Michael Dolph, Hoora Moradian, Samantha Slaff, Yu-Hsuan Shih, Derek Tang

{"title":"Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison.","authors":"Faiz Anwer, Tommy Lan, Michael Dolph, Hoora Moradian, Samantha Slaff, Yu-Hsuan Shih, Derek Tang","doi":"10.1080/14796694.2024.2426443","DOIUrl":null,"url":null,"abstract":"Aims: Limited head-to-head data exist for daratumumab plus pomalidomide and dexamethasone (DPd) and non-pomalidomide-containing triplet regimens to treat relapsed/refractory multiple myeloma (RRMM). This study conducted population-adjusted indirect comparisons of overall survival (OS) for DPd vs. daratumumab, carfilzomib, and dexamethasone (DKd) and daratumumab, bortezomib, and dexamethasone (DVd).Materials & methods: A systematic literature review was performed via searches of databases and relevant conference proceedings. Both simulated treatment comparison (STC) and matching-adjusted indirect comparison (MAIC) were used to adjust for between-trial differences.Results: Seven randomized controlled trials were identified, five of which were subsequently excluded from the indirect treatment comparison during feasibility assessment. A consistent OS benefit was observed for DPd vs. DKd and DVd for patients with RRMM, using both STC and MAIC methods.Conclusions: The findings of this study support the use of DPd over DKd and DVd for the treatment of patients with early RRMM.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"221-230"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792785/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2426443","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Limited head-to-head data exist for daratumumab plus pomalidomide and dexamethasone (DPd) and non-pomalidomide-containing triplet regimens to treat relapsed/refractory multiple myeloma (RRMM). This study conducted population-adjusted indirect comparisons of overall survival (OS) for DPd vs. daratumumab, carfilzomib, and dexamethasone (DKd) and daratumumab, bortezomib, and dexamethasone (DVd).

Materials & methods: A systematic literature review was performed via searches of databases and relevant conference proceedings. Both simulated treatment comparison (STC) and matching-adjusted indirect comparison (MAIC) were used to adjust for between-trial differences.

Results: Seven randomized controlled trials were identified, five of which were subsequently excluded from the indirect treatment comparison during feasibility assessment. A consistent OS benefit was observed for DPd vs. DKd and DVd for patients with RRMM, using both STC and MAIC methods.

Conclusions: The findings of this study support the use of DPd over DKd and DVd for the treatment of patients with early RRMM.

查看原文本刊更多论文

早期RRMM患者使用DPd与其他三联治疗的生存趋势：人群调整间接治疗比较

目的：达拉单抗联合泊马度胺和地塞米松（DPd）和不含泊马度胺的三重方案治疗复发/难治性多发性骨髓瘤（RRMM）的试验数据有限。该研究对DPd与达拉单抗、卡非佐米和地塞米松（DKd）和达拉单抗、硼替佐米和地塞米松（DVd）的总生存期（OS）进行了人群调整后的间接比较。材料与方法：通过检索数据库和相关会议记录进行系统的文献综述。采用模拟治疗比较（STC）和匹配调整间接比较（MAIC）来调整试验间差异。结果：共确定了7个随机对照试验，其中5个在可行性评估时被排除在间接治疗比较之外。在使用STC和MAIC方法的RRMM患者中，DPd与DKd和DVd相比，观察到一致的OS获益。结论：本研究结果支持使用DPd而不是DKd和DVd治疗早期RRMM患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.